A Safety and Efficacy Study Evaluating CTX112 in Subjects With Relapsed or Refractory B-Cell Malignancies

Exclusion Criteria

• •1. Prior allogeneic hematopoietic stem cell transplant (HSCT).
• •2. Active or history of central nervous system (CNS) involvement by malignancy.
• •3. History of a seizure disorder, cerebrovascular ischemia/hemorrhage, dementia, cerebellar disease, or any autoimmune disease with CNS involvement.
• •4. Presence of bacterial, viral, or fungal infection that is uncontrolled or requires IV anti-infectives.
• •5. Active HIV, hepatitis B virus or hepatitis C virus infection.
• •6. Previous or concurrent malignancy in the last 3 years (with the exception of non-melanoma skin cancer and other cancers deemed by the investigator and medical monitor to be of low likelihood for recurrence).
• •7. Concurrent systemic treatment with an anticancer biologic (e.g., monoclonal antibody) within 30 days prior to CTX112 infusion or with a nonbiological anticancer drug within 14 days prior to CTX112 infusion.
• •8. Primary immunodeficiency disorder or active autoimmune disease requiring steroids and/or other immunosuppressive therapy.
• •9. Women who are pregnant or breastfeeding.